Exicure was an expiring company with no money or active pipeline. | A couple of months ago, Exicure was an expiring company ...
Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...
Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.
Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...
SAN FRANCISCO--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage ... In addition, we announced our second lead pipeline program for the treatment of acromegaly with clinical development ...
pipeline, and anticipated milestones for 2025 and beyond at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 7:30 a.m. PT. Nimbus Therapeutics is a clinical-stage ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to ...
The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its pipeline product candidates are CTX-471 ...
HONOLULU, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Krilla Kaleiwahea LLC (K2), a Native Hawaiian Organization leader in defense, technology, resilience, and workforce development for the U.S. federal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback